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Relation of severe COVID-19 in Scotland
to transmission-related factors and risk
conditions eligible for shielding support:
REACT-SCOT case-control study
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Stuart McGurnaghan6, Matthew Armstrong2, Joke Delvaux2, Sam Colville2, Sharon Hutchinson2,4,
Chris Robertson2,5, Nazir Lone1, Jim McMenamin2, David Goldberg2 and Helen M. Colhoun2,6*
Abstract
Background: Clinically vulnerable individuals have been advised to shield themselves during the COVID-19
epidemic. The objectives of this study were to investigate (1) the rate ratio of severe COVID-19 associated with
eligibility for the shielding programme in Scotland across the first and second waves of the epidemic and (2) the
relation of severe COVID-19 to transmission-related factors in those in shielding and the general population.
Methods: In a matched case-control design, all 178,578 diagnosed cases of COVID-19 in Scotland from 1 March 2020
to 18 February 2021 were matched for age, sex and primary care practice to 1,744,283 controls from the general
population. This dataset (REACT-SCOT) was linked to the list of 212,702 individuals identified as eligible for shielding.
Severe COVID-19 was defined as cases that entered critical care or were fatal. Rate ratios were estimated by
conditional logistic regression.
Results: With those without risk conditions as reference category, the univariate rate ratio for severe COVID-19 was
3.21 (95% CI 3.01 to 3.41) in those with moderate risk conditions and 6.3 (95% CI 5.8 to 6.8) in those eligible for
shielding. The highest rate was in solid organ transplant recipients: rate ratio 13.4 (95% CI 9.6 to 18.8). Risk of severe
COVID-19 increased with the number of adults but decreased with the number of school-age children in the
household. Severe COVID-19 was strongly associated with recent exposure to hospital (defined as 5 to 14 days before
presentation date): rate ratio 12.3 (95% CI 11.5 to 13.2) overall. The population attributable risk fraction for recent
exposure to hospital peaked at 50% in May 2020 and again at 65% in December 2020.
Conclusions: The effectiveness of shielding vulnerable individuals was limited by the inability to control transmission
in hospital and from other adults in the household. Mitigating the impact of the epidemic requires control of
nosocomial transmission.
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Background
The SARS-CoV-2 pandemic reached Scotland in early
2020 with the first positive laboratory test recorded on
1 March 2020. Population-wide interventions included
advice that symptomatic individuals should self-isolate,
banning of mass gatherings, closure of schools and finally
a population-wide lockdown on 23March 2020. Although
no systematic studies of risk factors were available at that
time, public health agencies issued lists of “moderate risk”
conditions [1] and “diseases and conditions considered to
be very high risk” [2]. Those with “very high risk” con-
ditions were designated as eligible for shielding and were
sent letters advising strict isolation, even from othermem-
bers of the same household, and offering support which
included a national opt-in scheme of free food delivery,
home delivery of medication and priority access to super-
market delivery slots. Those living in multiple-occupancy
households were advised to isolate from other household
members. Compliance was voluntary.
For this study, the research question was to investi-
gate the effectiveness of the shielding programme indi-
viduals and to identify avoidable factors that might have
limited the effectiveness of this focused protection of vul-
nerable individuals. The original aim was to investigate
whether shielding advice and support had reduced the
risk of COVID-19. The first objective was to quantify
the incidence of severe COVID-19 in those eligible for
shielding and to determine whether the rate ratio asso-
ciated with eligibility for shielding compared to those
without risk conditions had fallen after the receipt of
shielding letters. The second objective was to understand
the relation of severe COVID-19 in those eligible for
shielding to transmission-related factors including house-
hold composition and recent exposure to hospital. As
the relevance of these transmission-related factors among
those eligible for shielding became clear, the aims were
broadened to investigate the relation of severe COVID-




The original protocol for the REACT-SCOT case-control
study was registered with the European Network of Cen-
tres for Pharmacoepidemiology and Pharmacovigilance
(ENCEPP number EUPAS35558). We linked a national
dataset of those eligible for shielding to a case-control
dataset (REACT-SCOT) established in Public Health
Scotland (PHS) that includes all persons diagnosed with
COVID-19 in Scotland. Each case wasmatched to up to 10
controls of the same sex and in the same 1-year age band,
registered with the same primary care practice and not
previously diagnosed with COVID-19, who were alive on
the date of presentation of the case controls [3]. This case-
control dataset is refreshed every few weeks and linked to
health records that are used to assign a list of designated
“moderate risk conditions”. Thus all cases and controls
were classified into three categories: no risk condition,
moderate risk condition only and eligible for shielding. As
a first step, we report the cumulative incidence of diag-
nosed COVID-19 among those in shielding. For all tests
of association and comparisons of rates between groups,
we limit the analysis to severe cases and their respective
controls as described below, and we exclude care home
residents.
The study period was from 1March 2020 (the date of the
first case in Scotland ) to 18 February 2021 (date of the lat-
est data extract available for this study). Thus, it predates
the start of the shielding programme.
Ascertainment of eligibility for shielding
The list of those eligible for shielding was generated
by Public Health Scotland from March 2020 onwards
by querying health-care information systems including
hospital discharge records, prescription encashments,
regional cancer chemotherapy databases, blood and trans-
plant registries, for a designated list of diseases and con-
ditions, supplemented direct requests to clinicians in rel-
evant specialties [4]. The categories designated as eligible
for shielding were as listed below [2, 4]:
1. Solid organ transplant recipient
2. Cancer of the blood or bone marrow at any stage of
treatment, or people with cancer receiving
treatments that affect the immune system
3. Severe respiratory conditions including cystic
fibrosis, severe asthma and severe chronic
obstructive airway disease, on home oxygen, severe
bronchiectasis, pulmonary hypertension)
4. Rare diseases that increase the risk of infections such
as severe combined immunodeficiency and
homozygous sickle-cell disease
5. People on immunosuppression therapies sufficient to
increase risk of infection
6. Pregnant with heart disease
7. Additional conditions, including people on renal
dialysis, those who had a splenectomy and others
identified by clinicians as requiring shielding advice.
The first batch of shielding letters was sent on 3 April
2020. Further batches were issued on a weekly basis and
the programme was paused on 1 August 2020. On 25
November 2020, a further letter was issued with “extra
protection level advice for people at highest risk” based on
the current protection level for the population level in that
area. The list of those eligible for shielding has been reg-
ularly updated: this study is based on the list of 212,702
individuals identified up to 28 January 2021.
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Ascertainment of cases and sampling of controls
Case ascertainment for the REACT-SCOT study has been
described in detail elsewhere [3]. Case ascertainment was
based on querying the following national-level databases:
Electronic Communication of Surveillance in Scotland
(ECOSS) that captures virology testing in all NHS labo-
ratories, National Records of Scotland (NRS) death reg-
istrations, RAPID which is a daily update of hospitalisa-
tions and Scottish Morbidity Record 01 (SMR01) which
records general hospital discharges including day cases
and is ICD-10 coded. All these databases use the Com-
munity Health Index (CHI) number as identifier. The CHI
database includes age, sex, postcode and care home sta-
tus and can be queried to extract numbers of adults and
children in the household.
Cases diagnosed with COVID-19 were defined as those
with a positive nucleic acid test for SARS-CoV-2 in
ECOSS, a hospital discharge diagnosis of COVID-19 in
SMR01, or a death registration with mention of COVID-
19 anywhere on the death certificate. Thus, not all those
cases defined as having evidence of COVID-19 had a pos-
itive test. To restrict cases to those with a positive test
would have missed a large proportion of deaths in the
first wave as the availability of tests was restricted. Some
cases with a definite clinical diagnosis of COVID-19 based
on typical presentation and radiological signs nonetheless
tested negative when they presented late in their illness.
In the first wave (up end of August 2020), only 3136
(68%) of the severe cases were test-positive; in the second
wave beginning on 1 September 2020, 5847 (96%) were
test-positive.
The presentation date was assigned as the date of the
first positive test for those ascertained through testing,
as 7 days before the admission date for those without a
positive test result ascertained through hospital discharge
records, and as 14 days before the date of death for those
without a positive test result ascertained through death
certificates. Databases were queried from 1 March 2020
(date of the first diagnosed case of COVID-19 in Scotland)
up to 18 February 2021 for test results and 12 February
2021 for deaths. For each case diagnosed with COVID-
19, up to 10 community controls matched for sex, 1-year
age band and primary care practice were selected from the
CHI database and assigned the same presentation date as
the case. With this incidence density sampling design, it is
possible and correct for an individual to appear more than
once as a control and subsequently as a case. As primary
care practice catchment areas are localised, matching on
primary care practice matches for geographic factors also.
Inclusion and exclusion criteria for analyses
We reported the cumulative incidence of diagnosed
COVID-19 in the shielded and further categorised these
cases into those that required critical care or were fatal
or not. We defined severe COVID-19 as those diagnosed
with COVID-19 who also required entry to critical care
within 21 days of presentation date, or had a fatal out-
come. Entry to critical care units—intensive care, high
dependency or combined units—was obtained by linkage
to the Scottish Intensive Care Society and Audit Group
(SICSAG) database. Fatal outcome was defined as death
at any time with COVID-19 coded as underlying cause,
death from any cause within 28 days of testing positive
or death within 28 days of presentation date for cases
ascertained only through discharge records.
For all subsequent tests of association and comparisons
of rates between groups presented here, we restricted the
dataset to cases with severe COVID-19 and their matched
controls from the population. The narrow definition of
severe COVID-19 was defined as the main outcome mea-
sure of the REACT-SCOT study at the design stage, to
ensure that ascertainment would not be biased by varia-
tion in testing policies or selection for hospitalisation. In
the first wave in Scotland, people with symptoms were
advised to stay at home and not to seek testing or attend
hospital unless their condition deteriorated. A broader
case definition based on test-positive or hospitalised cases
would have given rise to selection bias if, for equiva-
lent severity of symptoms, those with pre-existing risk
conditions were more likely to be tested or hospitalised
than those without pre-existing risk conditions. For all
tests of association and comparisons of rates between
groups other than the initial tabulation of cumulative inci-
dence of any diagnosis of COVID-19 in the shielded, we
excluded care home residents because policies for shield-
ing care home residents are different from those relevant
to shielding individuals living independently.
Linkage of cases and controls to demographic and
morbidity data
Linkage of cases and controls to demographic and mor-
bidity data and the associations of these factors with
severe COVID-19 have been described in detail elsewhere
[3]. Cases and controls were linked to hospital discharge
ICD-10 codes over the last 5 years in SMR01, to British
National Formulary codes of dispensed prescriptions in
the 240 days before presentation date in the Prescribing
Information System and to the national register of dia-
betes. We used these linked datasets to assign a list of
“moderate risk conditions” for COVID-19 designated by
public health agencies [1]: diabetes, heart disease, asthma
or chronic airway disease, chronic kidney disease, dis-
abling neurological conditions and immune deficiency or
suppression. The codes used are as described previously
[3]. Three broad risk groups were defined: no risk con-
dition, moderate risk condition but ineligible for shield-
ing, and eligible for shielding. Socioeconomic status was
assigned as the Scottish Index of Multiple Deprivation
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(SIMD) score which is based on linkage of postcodes to
Census data [5]; quintile 5 is the least deprived.
Transmission-related risk factors
As addresses in the CHI database have been mapped
to Unique Property Reference Numbers, it was possible
to calculate the numbers of adults and children in each
household and to augment the coding of care home res-
idence in the CHI database. Care home residence was
assigned using the field in the CHI database, augmented
by coding as care home residents the 4548 individuals
aged over 70 in households with 10 or more adults to
give a total of 26,057 care home residents out of the
1,922,861 cases and controls. Linkage to occupational sta-
tus for health-care workers and teachers was undertaken
as described elsewhere [6, 7].
We used the Scottish Morbidity Records SMR01 (inpa-
tients and day cases) and SMR00 (outpatient attendance)
together with the RAPID database to derive variables
encoding recent exposure to hospitals. We defined the
variable “recent hospital exposure” as any hospital in-
patient stay, day case attendance or face-to-face out-
patient consultation from 5 to 14 days before presentation
date. Restriction of hospital exposure to this time win-
dow was intended to exclude consultations caused by
COVID-19 symptoms for which testing was delayed by
a few days, but to include those exposed to health care
facilities in the time interval during which the infection
was likely to have been acquired. In Scotland, people
with COVID-19 symptoms were instructed not to visit
hospitals, to attend designated test centres for testing
within 3 days and to call an emergency number for admis-
sion if their symptoms worsened. It is therefore unlikely
that hospital visits by people with COVID-19 symptoms
could account for the association of first positive tests
5–6 days before. As the average incubation period for
COVID-19 is 5–6 days [8], exposure in the time window is
relevant.
Our intention was to capture all relevant exposure in
cases and controls, rather than to assign individual cases
as “health-care associated COVID-19” as specified by
the European Centre for Disease Prevention and Control
(ECDC) [9]. The ECDC definition of probable/definite
health-care-associated COVID-19 is restricted to those
who have been in hospital for at least 8 days before
first developing symptoms: all other cases are classified
as community onset. The definition of “recent hospi-
tal exposure” used in this study was intended to cap-
ture all those whose infection could have been acquired
in hospital (sensitivity of 1), unlike the ECDC defini-
tion of “probable/definite health-care associated infec-
tion” which is intended to identify those whose infection
was unlikely to have been acquired outside hospital (high
specificity). Because this study includes a control group,
the calculation of the population attributable risk fraction
is valid if the classification of exposure has sensitivity of 1
even if the specificity is less than 1 [10]. For estimating the
population attributable risk fraction, it is therefore appro-
priate to use an inclusive definition of exposure, even if
this includes some individuals whose infection was not
acquired in hospital.
Statistical methods
Other than the cumulative incidence analyses, the analy-
ses presented here focus on severe COVID-19 and their
respective controls. For the matched case-control analy-
ses, severe cases and their respective controls were cen-
sored at date of first vaccination.
Among all severe cases and controls, conditional odds
ratios for severe COVID-19 associated with eligibility for
shielding and for other moderate risk conditions were
calculated with “no risk condition” as reference category
using conditional logistic regression. With this incidence
density design, the conditional odds ratios are equiva-
lent to rate ratios so are referred to as such throughout
the manuscript. As the community controls were drawn
by incidence density sampling and matched for age, sex
and general practice, the conditional logistic regression
inherently controls for these variables and for calendar
time. Conditional logistic regression was also used to test
for association of transmission-related factors with severe
COVID-19. These transmission-related factors were cho-
sen a priori as factors that would plausibly constrain the
extent to which individuals were able to limit their expo-
sure to infection: the need for hospital care, deprivation
score since it may relate to overcrowding or the economic
imperative to work, number of persons in the house-
hold and usual occupation. A multivariable model was
used to adjust for shielding condition, moderate risk con-
dition and transmission-related factors simultaneously.
These analyses were repeated restricted to those eligible
for shielding. The multivariable analyses in Tables 2 and 3
are simultaneously adjusted for all variables shown in the
table.
To plot the time course of the rate ratios for severe
COVID-19 associated with eligibility for shielding and
with hospital exposure, these rate ratios were estimated
over 21-day sliding windows of calendar time. The popu-
lation attributable risk fraction of severe cases for hospital
exposure was calculated in each 21-day time window
from Miettinen’s formula as pc (r − 1) /r, where pc is the
frequency of exposure in cases and r is the rate ratio [10].
Sliding windows of size 3, 7 and 21 days were used to
plot the number of severe cases, the frequency of recent
hospital exposure and the rate ratios associated with hos-
pital exposure and household composition. In the plots of
exposure frequency and rate ratio, the data points from
1 June 2020 to 30 September 2020 were omitted as the
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numbers of severe cases and controls were too low for
estimates of frequencies and rate ratios to be accurate.
To test for causality of the association of recent expo-
sure to hospital with severe COVID-19, we estimated the
conditional odds ratios associated with recent hospital
exposure (5 to 14 days before first testing positive) with
less recent exposure (15 to 24 days before first testing pos-
itive) as reference category. This analysis was restricted
to test-positive severe cases and their matched controls,
so that it does not rely on the imputed presentation dates
that were assigned to test-negative cases. The classic case-
crossover design compares in cases only the frequencies
of exposure in recent and less recent time windows and
estimates the conditional odds ratio as the ratio of num-
ber of cases with recent exposure only to number of cases
with less recent exposure only. This can be viewed as a
matched-pairs case-control study in which the case and
control are the same person in recent and less recent time
windows [11]. The analysis that we report is a refinement
that takes advantage of the availability of a matched con-
trol group to estimate the rate ratio for severe COVID-19
associated with exposure only in a recent time window,
with those exposed only in a less recent time window
as the reference category. This controls for any differ-
ence in the population frequencies of exposure or disease
incidence between recent and less recent time windows.
Results
Shielding eligibility and risk of COVID-19
Additional file 1: Table S1 shows the frequency of risk
categories in those eligible for shielding. To comply with
statistical disclosure control rules, the 58 women in the
category “pregnant with heart disease” have been allo-
cated to the “Additional conditions” category; there were
no severe cases in this group. Table 1 shows the number in
each category of eligibility for shielding by case status clas-
sified as not diagnosed, not severe or severe COVID-19;
among 212,702 persons eligible for shielding, 6081 (2.9%)
were diagnosed with COVID-19 but did not enter criti-
cal care or die within 28 days, 359 (0.2%) entered critical
care for COVID-19 but survived and 1559 (0.7%) had a
fatal outcome. As shown in Fig. 1, the time course of fre-
quency of daily severe cases in those eligible for shielding
broadly paralleled the time course in those without risk
conditions. Of the 1926 severe cases among those eligible
for shielding, 286 were resident in care homes.
Rate ratios for severe COVID-19 by risk group
Table 2 shows the rate ratios for severe COVID-19 associ-
ated with each category of shielding eligibility, with those
without risk conditions as reference category, excluding
care home residents. The univariate rate ratio for severe
disease was 3.21 (95% CI 3.01 to 3.41, p<0.001) in those
with moderate risk conditions and 6.3 (95% CI 5.8 to 6.8,
p<0.001) in those eligible for shielding. The rate ratio asso-
ciated with eligibility for shielding was 6.1 (95% CI 5.4 to
7.0) up to the end of August 2020 and 6.4 (95% CI 5.8 to
7.0) after August 2020.
Among those eligible for shielding, solid organ trans-
plant recipients were the group at highest risk, with a
univariate rate ratio of 13.4 (95% CI 9.6 to 18.8, p<0.001)
for severe COVID-19. On multivariable adjustment for
the covariates shown in Table 2, the rate ratios for all these
shielding groups remained high.
We examined the time course of the rate ratio associated
with eligibility for shielding. As shown in Additional file 1:
Table S2, most of the solid organ transplant recipients,
those with severe respiratory disease and cancer patients
were included in the first batch of shielding letters sent on
3 April 2020. Additional file 1: Figure S1(a) shows that the
rate ratio associated with eligibility for shielding increased
from 5.17 in the time window with mid-point 1 April to
8.89 in the time window with mid-point 1 May. The rate
ratio associated with moderate risk conditions also rose
Table 1 Frequencies of any diagnosis of COVID-19, entry to critical care and fatal outcome among those eligible for shielding, by
eligibility category, up to 18 February 2021
Diagnosed with COVID-19
Not diagnosed with COVID-19 No critical care, non-fatal Critical care, non-fatal Fatal All
All shielding categories 204,703 (96.2%) 6081 (2.9%) 359 (0.2%) 1559 (0.7%) 212,644
Shielding eligibility category
Solid organ transplant 6620 (96.3%) 188 (2.7%) 24 (0.3%) 40 (0.6%) 6872
Specific cancers 25,788 (96.6%) 652 (2.4%) 36 (0.1%) 223 (0.8%) 26,699
Severe respiratory 83,268 (96.2%) 2432 (2.8%) 131 (0.2%) 768 (0.9%) 86,599
Rare diseases 10,673 (96.4%) 300 (2.7%) 14 (0.1%) 85 (0.8%) 11,072
On immunosuppressants 30,796 (96.8%) 866 (2.7%) 42 (0.1%) 103 (0.3%) 31,807
Additional conditions 47,501 (95.8%) 1642 (3.3%) 112 (0.2%) 340 (0.7%) 49,595
Percentages are row percentages
Severe cases are those that entered critical care or were fatal
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Fig. 1 Area plot of severe cases by vulnerability category and date of presentation, excluding care home residents
in the first half of May, but fell more rapidly than the rate
ratio associated with eligibility for shielding. Thus, there
was no evidence that shielding advice reduced the rate
ratio.
Associations of severe COVID-19 with transmission-related
factors
Associations in those eligible for shielding
Table 3 shows associations with risk factors among those
eligible for shielding only, with severe respiratory disease
(the largest category) as reference category. The rate ratio
increased with the number of adults in the household but
not with the number of children. The strongest risk factor
for severe COVID-19 among those eligible for shielding
was recent exposure to hospital, with a rate ratio of 6.0
(95% CI 4.7 to 7.7, p<0.001) in the multivariable model
which all the covariates shown in the table were entered
simultaneously. Of severe cases among those eligible for
shielding, 739 (45%) had recent exposure to hospital.
Using Miettinen’s formula as given above, the population
attributable risk fraction for recent exposure to hospital in
those eligible for shielding can thus be calculated as 37%
of severe cases.
Associations in the overall population
Table 2 shows the association of severe COVID-19 with
risk factors in the general population, including those eli-
gible for shielding but excluding residents in care homes.
The risk of severe COVID-19 increased with the number
of adults in the household, but was inversely associated
with the number of school-age children in the house-
hold in a multivariable model in which all the covariates
in Table 2 were entered simultaneously. The rate ratio
associated with two or more adults (with single-adult
households as reference category) was 2.08 (95% CI 1.95
to 2.21, p<0.001) and the rate ratio associated with one
or more school-age children was 0.72 (95% CI 0.64 to
0.81, p<0.001). The other demographic factor associated
with increased risk was socioeconomic deprivation: the
rate ratio in the least deprived quintile compared with
the most deprived quintile was 0.60 (95% CI 0.53 to 0.66,
p<0.001). As shown in Additional file 1: Figure S1(b), in
a joint model with number of adults in household, num-
ber of children in household, and SIMD deprivation score
the rate ratio for severe disease per adult in household
remained in the range 1.5 to 2 throughout the epidemic,
and the rate ratio per school-age child in household
remained mostly in the range 0.7 to 1.
As reported previously, in comparison with other occu-
pations patient-facing health-care workers were at higher
risk of severe disease with a rate ratio of 1.80 (95% CI 1.50
to 2.16, p<0.001), and teachers were at lower risk with a
rate ratio of 0.35 (95% CI 0.19 to 0.64, p<0.001).
Association with recent exposure to hospital As
Table 2 shows, the strongest risk factor (in terms of
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Table 2 Rate ratios for severe COVID-19 in those not resident in care homes
Univariate Multivariable
Controls (86,902) Cases (7217) Rate ratio (95% CI) p-value Rate ratio (95% CI) p-value
No risk condition 45,354 (52%) 1897 (26%) . .
Moderate risk condition 33,909 (39%) 3702 (51%) 3.20 (3.01, 3.41) <0.001 2.67 (2.50, 2.85) <0.001
Shielding eligibility category
Solid organ transplant 112 (0%) 59 (1%) 13.4 (9.6, 18.8) <0.001 7.0 (4.6, 10.4) <0.001
Specific cancers 907 (1%) 240 (3%) 7.9 (6.8, 9.3) <0.001 3.47 (2.87, 4.19) <0.001
Severe respiratory 3751 (4%) 733 (10%) 5.8 (5.2, 6.4) <0.001 4.32 (3.87, 4.83) <0.001
Rare diseases 341 (0%) 69 (1%) 7.0 (5.3, 9.3) <0.001 4.68 (3.37, 6.49) <0.001
On immunosuppressants 742 (1%) 126 (2%) 4.61 (3.76, 5.65) <0.001 3.26 (2.59, 4.10) <0.001
Additional conditions 1786 (2%) 391 (5%) 6.6 (5.8, 7.5) <0.001 4.31 (3.72, 5.00) <0.001
At least one child under 5 1759 (2%) 150 (2%) 0.87 (0.73, 1.04) 0.1 0.73 (0.60, 0.89) 0.002
Number of school age children in household
0 school age 80,885 (93%) 6685 (93%) . .
1 school age 1749 (2%) 93 (1%) 0.54 (0.43, 0.67) <0.001 0.76 (0.60, 0.96) 0.02
2 or more 4268 (5%) 439 (6%) 1.06 (0.95, 1.19) 0.3 0.71 (0.62, 0.80) <0.001
Number of adults in household
1 adult 62,011 (72%) 4259 (59%) . .
2 adults 19,190 (22%) 1951 (27%) 1.57 (1.48, 1.67) <0.001 1.80 (1.68, 1.92) <0.001
3 to 4 4611 (5%) 769 (11%) 2.50 (2.28, 2.74) <0.001 3.19 (2.87, 3.54) <0.001
5 to 9 326 (0%) 85 (1%) 3.98 (3.10, 5.11) <0.001 5.8 (4.3, 7.7) <0.001
10 or more 247 (0%) 102 (1%) 10.6 (7.6, 14.6) <0.001 11.4 (8.0, 16.2) <0.001
SIMD quintile
1 - most deprived 21,388 (25%) 2162 (30%) . .
2 19,072 (22%) 1761 (24%) 0.91 (0.85, 0.98) 0.01 0.95 (0.88, 1.03) 0.3
3 15,399 (18%) 1264 (18%) 0.76 (0.70, 0.82) <0.001 0.84 (0.76, 0.92) <0.001
4 14,870 (17%) 1079 (15%) 0.65 (0.59, 0.70) <0.001 0.72 (0.65, 0.79) <0.001
5 - least deprived 16,084 (19%) 944 (13%) 0.53 (0.48, 0.58) <0.001 0.60 (0.53, 0.66) <0.001
Occupation
Other / undetermined 84,672 (98%) 6962 (97%) . .
Teacher 336 (0%) 11 (0%) 0.35 (0.19, 0.64) <0.001 0.42 (0.22, 0.81) 0.01
Health care, not PF / undetermined 826 (1%) 87 (1%) 1.18 (0.94, 1.47) 0.2 1.20 (0.94, 1.53) 0.2
Health care PF 846 (1%) 145 (2%) 1.80 (1.50, 2.16) <0.001 1.86 (1.52, 2.27) <0.001
Recent hospital visit/stay 3565 (4%) 2415 (33%) 12.3 (11.5, 13.2) <0.001 10.2 (9.5, 11.0) <0.001
Severe COVID-19 is defined by entry to critical care or fatal outcome
Percentages are column percentages for each variable
PF, patient-facing
Rate ratios are from conditional logistic regression models with cases and controls matched for age, sex and general care practice
Univariate rate ratios are for models with a single covariate
Multivariable rate ratios are for a model including all covariates shown in the table
deviance explained) for severe COVID-19 in the overall
population was recent exposure to hospital: rate ratio 12.3
(95% CI 11.5 to 13.2, p<0.001). Exclusion of the 11% of
those dying within 28 days of a positive test who did not
have COVID-19 as underlying cause of death on their
death certificates changed this rate ratio only slightly to
11.9 (11.0, 12.8).
Figure 2a shows the time course of the frequency of
recent exposure to hospital using data from controls; for
monitoring background exposure levels, it is appropri-
ate to examine the frequency in controls rather than in
cases. Recent exposure to hospital fell precipitously when
restrictions on non-COVID-19 admission were imposed
in March, but remained higher in those eligible for shield-
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Table 3 Rate ratios for severe COVID-19 associated with risk conditions (with severe respiratory disease as reference category) in those
eligible for shielding and not resident in care homes
Univariate Multivariable
Controls (7808) Cases (1640) Rate ratio (95% CI) p-value Rate ratio (95% CI) p-value
Shielding eligibility category
Severe respiratory 3834 (49%) 744 (45%) . .
Solid organ transplant 112 (1%) 60 (4%) 1.58 (0.90, 2.77) 0.1 1.36 (0.70, 2.63) 0.4
Specific cancers 925 (12%) 240 (15%) 1.28 (0.98, 1.66) 0.07 0.88 (0.64, 1.21) 0.4
Rare diseases 348 (4%) 72 (4%) 1.18 (0.75, 1.84) 0.5 1.14 (0.68, 1.91) 0.6
On immunosuppressants 759 (10%) 129 (8%) 0.74 (0.53, 1.03) 0.07 0.82 (0.56, 1.20) 0.3
Additional conditions 1830 (23%) 395 (24%) 1.19 (0.95, 1.49) 0.1 1.00 (0.77, 1.31) 1
At least one child under 5 66 (1%) 27 (2%) 0.80 (0.32, 2.02) 0.6 0.45 (0.15, 1.31) 0.1
School-age children in household
0 school age 7537 (97%) 1545 (94%) . .
1 school age 82 (1%) 19 (1%) 0.36 (0.13, 0.99) 0.05 0.84 (0.29, 2.45) 0.7
2 or more 189 (2%) 76 (5%) 1.03 (0.60, 1.76) 0.9 0.74 (0.40, 1.37) 0.3
Adults in household
1 adult 5811 (75%) 1010 (62%) . .
2 adults 1647 (21%) 458 (28%) 1.60 (1.30, 1.97) <0.001 1.74 (1.37, 2.21) <0.001
3 or more 339 (4%) 167 (10%) 2.15 (1.51, 3.07) <0.001 2.52 (1.66, 3.82) <0.001
SIMD quintile (integer) 2 (1–4) 2 (1–4) 0.97 (0.91, 1.05) 0.5 0.98 (0.90, 1.06) 0.6
Recent hospital visit/stay 840 (11%) 739 (45%) 5.8 (4.6, 7.4) <0.001 6.0 (4.7, 7.7) <0.001
Severe COVID-19 is defined by entry to critical care or fatal outcome
Percentages are column percentages for each variable
Rate ratios are from conditional logistic regression models matched for age, sex and general practice
Univariate rate ratios are for models with a single covariate
Multivariable rate ratios are for a model including all covariates shown in the table
ing than in those with moderate risk conditions or no risk
conditions throughout.
As shown in Fig. 2b, the rate ratio associated with recent
exposure to hospital increased from 8 in the time window
with mid-point 1 April to a rate ratio of 31 in the time
window with mid-point 1 May.
The population attributable risk fraction of severe
COVID-19 for recent exposure to hospital in the general
population can be calculated as 30% over the study period.
This fraction reached a peak in the first wave of 50% of
severe cases at the beginning ofMay, declined rapidly over
the next few weeks and increased again to 65% of severe
cases at the beginning of December (Fig. 2c).
In a post hoc analysis, we found that the association of
recent exposure to hospital with severe disease was largely
driven by inpatient exposure [rate ratio 33.6 (95% CI 30.4
to 37.3, p<0.001)]; the rate ratios associated with day case
exposure [2.59 (95% CI 1.87 to 3.58, p<0.001)] or outpa-
tient exposure [2.67 (95% CI 2.40 to 2.97, p<0.001)] were
much lower. To test if the association of severe COVID-
19 with recent inpatient exposure was likely to simply
reflect confounding by time invariant comorbidity, the
association was examined by time window as described in
the “Methods” section. Table 4 shows that the rate ratio
for severe COVID-19 associated with inpatient exposure
only in the recent interval (days 5 to 14 before testing pos-
itive), with exposure only in the less recent interval (days
15 to 24 before testing positive) as reference category was
5.9 (95% CI 3.6 to 9.7, p<0.001).
The frequency of recent inpatient exposure over the
period of study in cases not resident in care homes was
28%. From this and the rate ratio of 33.6, the popula-
tion attributable risk fraction for recent hospital inpatient
exposure can be calculated from Miettinen’s formula as
27%. As Additional file 1: Table S3 shows, most of the dif-
ference in inpatient exposure classification of severe cases
between our definition and the ECDC definition arises
because cases with onset after hospital discharge would be
classified as community onset by the ECDC classification:
only 57% of severe cases with inpatient exposure 5–14
days before COVID-19 presentation would be defined as
probable or definite hospital-acquired infection (in hos-
pital for at least 8 days before first testing positive) by
the ECDC classification. The rate ratio for severe disease
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Fig. 2 a Recent hospital exposure by risk group and 7-day sliding window of presentation dates. b Rate ratio for severe COVID-19 associated with
recent hospital exposure in those not resident in care homes. c Fraction of severe cases attributable to recent hospital exposure in those not
resident in care homes
Table 4 Rate ratios for severe COVID-19 by time window of hospital in-patient exposure, excluding care home residents
Time window of exposure Controls Cases Rate ratio (95% CI) p-value
Less recent interval only 494 (29%) 147 (6%) .
Recent interval only 470 (28%) 799 (35%) 5.9 (3.6, 9.7) <0.001
Both intervals 741 (43%) 1335 (59%) 6.9 (4.3, 11.1) <0.001
Rate ratios are from conditional logistic regression models
Dataset restricted to those exposed at some time between 5 and 24 days before first testing positive
Recent interval = days 5 to 14 before first testing positive, less recent interval = days 15 to 24 before first testing positive
Reference category is exposure in less recent interval only
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associated with being in hospital for at least 8 days before
presentation date was 45.4.
Discussion
Summary of findings and comparison with other studies
Key findings of this study were (1) that the rate ratios
for severe COVID-19 associated with shielding conditions
remained high through the epidemic; (2) that recent hos-
pital exposure and the number of adults in the household
were associated with severe COVID-19 among those eli-
gible for shielding and also in the general population; and
(3) that among those not resident in care homes the pro-
portion of severe cases attributable to hospital attendance
reached a peak of 65% during the second wave.
Risk to those eligible for shielding
In comparison with those with no risk condition, the high-
est rate ratio for severe COVID-19 was the 13-fold rate
ratio in solid organ transplant recipients. For other con-
ditions deemed eligible for shielding, the rate ratios were
between 5 and 8, compared to the rate ratio of about 3
associated with conditions designated as moderate risk,
which include heart disease, diabetes, chronic kidney dis-
ease and disabling neurological conditions. The numbers
of pregnant women with heart disease were too small for
the risk in this group to be estimated. Other studies of out-
come of COVID-19 in solid organ transplant recipients
and other individuals using immunosuppressants have
been based only on patients admitted to hospital [12, 13].
Such studies cannot assess the risks to immunosuppressed
individuals in the population.
The shielding programme was introduced at a time
when general social distancingmeasures were being intro-
duced and after the first lockdown had started. We had
hypothesised a priori that a fall in the rate ratio for severe
disease associated with eligibility for shielding within 2
weeks of the first letters being sent out would be consis-
tent with the shielding programme having some impact
beyond the population-wide lockdown that had been
imposed by this time. However, we did not find this; while
presentations of severe cases fell rapidly in the general
population from the beginning of April 2020, the fall in
presentations among those eligible for shielding advice
was delayed so that the rate ratio for severe COVID-
19 associated with eligibility for shielding rose during
April 2020. Daily deaths fell during April 2020 both in
those eligible and those ineligible for shielding. As a lock-
down on the general population had been imposed on
23 March 2020, and individuals who considered them-
selves to be at high risk would have been likely to reduce
their contact level before then, there were limited possibil-
ities for risk in this group to be reduced further by advice
to shield and offers of help in letters sent from 3 April
onwards.
Although we did not find any evidence that the shielding
programme per se reduced COVID-19 rates, it is possi-
ble that without shielding advice and support the outcome
in this group would have been worse. It is still relevant
to examine why advice to shield, combined with offers
of support for delivery of food and medicines, failed to
protect some individuals who were identified as clinically
extremely vulnerable. The association of severe COVID-
19 with recent hospital exposure in those who were eli-
gible for shielding, together with the increase in the rate
ratio associated with this exposure during periods when
population-wide social distancing measures were being
imposed, suggests that exposure to transmission in hospi-
tal settings is at least part of the explanation. Our finding
that the risk of severe COVID-19 was increased in those
who were sharing a household with other adults suggests
that this was another constraint on the effectiveness of
advice to shield, as no support was provided for other
householdmembers to co-isolate with the vulnerable indi-
vidual. A survey conducted online in the first 2 weeks of
June 2020 found that 65% of those living alone or shar-
ing a household with one other person reported that they
followed the guidance completely, but only 55% of those
living with two or more others did [14]. Development of
policies to overcome these constraints may lay a basis for
focused protection of the most vulnerable individuals to
be more effective in future epidemics.
Associationwith occupation andwith household composition
The increased risk of severe COVID-19 in patient fac-
ing health care workers is consistent with our previous
report of a threefold risk for hospitalised COVID-19 ear-
lier in the epidemic [6]. We and others have previously
reported lower risk in teachers compared with others of
the same age and sex [7, 15]. The inverse association of
severe disease with the number of school-age children
in the household extends and confirms the findings of
an earlier study of health care workers and their families
[16]. In the OPENSAFELY cohort, the rate ratio for fatal
COVID-19 associated with living with children aged 0–
11 years was 0.75 after adjusting for covariates, but no
dose-response relationship was reported [17].
The strong association of severe disease with number of
adults in the household is consistent with a recent esti-
mate, based on an intensive study of households in the
Netherlands, that the secondary attack rate for SARS-
CoV-2 infection is as high as 51% in adults [18]. We would
expect the risk of infection to increase with the num-
ber of other people in the household, especially where
population-wide social distancing between households
has been imposed. We might also expect that this associa-
tion would be strongest for severe disease, as the infecting
dose is likely to be higher in intra-household transmis-
sions than in transmissions between households. This is
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consistent with classic studies of other viral infections
showing that secondary cases in a household are more
severe than index cases [19]. The inverse association of
severe COVID-19 with number of children in the house-
hold, and the lower risk in teachers however suggests
that current or past exposure to children may have some
protective effect on adults. A possible explanation may
be that other coronaviruses generate cross-reactive T-cell
responses that may confer some resistance to SARS-CoV-
2 [20]. From a public health perspective the most relevant
implication is that although the rate ratio per child in the
household has been higher in the second wave of the epi-
demic than in the first wave, it has remained below 1 in
almost all time windows.
Association with recent exposure to hospital
A striking finding from our analysis is the population
attributable risk fraction of 30% for severe disease asso-
ciated with recent exposure to hospital. Although we had
pre-specified this category to include day case and out-
patient exposure, the association was driven by inpatient
exposure. The population attributable risk fraction asso-
ciated with inpatient exposure was 27%. The calculation
of the population attributable risk fraction for an expo-
sure provides an upper bound on the predicted effect of
removing that exposure. As explained in the “Methods”
section, for estimating the population attributable risk
fraction, it is appropriate to use an inclusive definition
of exposure that includes all those whose infection could
have been acquired in hospital. Using the ECDC defi-
nition of probable/definite nosocomial acquisition would
give a lower estimate of the proportion of severe cases
exposed to hospitals and the population attributable risk
fraction, because the ECDC definition excludes cases who
were not continuously in hospital for at least 8 days before
presenting.
The association of severe COVID-19 with recent hos-
pital admission is likely to be confounded by pre-existing
risk conditions. However adjusting for risk conditions in
a multivariable analysis reduced the rate ratio associated
with recent hospital exposure only slightly (from 12.3 to
10.2). The most compelling evidence of causality is the
time window analysis, which shows that the association of
disease is with elapsed time since exposure correspond-
ing to the known incubation period of SARS-CoV-2. The
rate ratio estimated from the time window analysis is
not directly comparable with the rate ratio based on the
case-control analysis because restriction to those with dis-
cordant exposure between time windows selects those
with fewer days in hospital (lower dosage of the exposure).
The role of nosocomial transmission was recognised
early in the COVID-19 epidemic. Hospital-acquired infec-
tion was suspected in 41% of hospitalised cases seen in
January 2020 in one centre in Wuhan [21]. A commen-
tary in April 2020 noted that “in Lombardy, SARS-CoV-
2 became largely a nosocomial infection” [22]. A study of
11 hospitals (10 in the UK) reported that 12.5% of hos-
pitalised cases of COVID-19 up to the end of April 2020
met the ECDC criterion for definite nosocomial infection
[23]. Most other reports have used the ECDC criterion for
probable/definite nosocomial infection. A study presented
to the UK Scientific Advisory Group on Emergencies in
January 2021 based on national data for hospital episodes
and COVID-19 tests in England linked to symptom onset
data from the COVID-19 Clinical Information Network
estimated that 27.6% of hospitalised cases up to the end
of July 2020 met this criterion and that onward trans-
mission of COVID-19 from hospital-acquired cases could
account for another 5% of hospitalised cases [24]. No sys-
tematic study of nosocomial cases has been reported for
England in the second wave: from routinely reported data
the proportion of hospitalised cases that met the crite-
rion for probable/definite nosocomial was estimated to be
18% in October 2020. For Scotland, the ARHAI (Antimi-
crobial Resistance and Healthcare Associated Infection)
unit of NHS National Services Scotland recently reported
that among those who died within 28 days of testing posi-
tive for COVID-19 (including care home residents) during
2020, 30%met the ECDC definition of probable or definite
nosocomial infection [25].
Strengths and limitations
Strengths of our study are the national coverage and the
comprehensive linkage to medical records and demo-
graphic risk factors. A limitation is that we do not have
primary care data other than encashed prescriptions.
Furthermore, as most immunosuppressant drugs are pre-
scribed through hospitals where linkage to prescribing
records is not yet possible, the risks associated with spe-
cific immunosuppressant drug classes could not be inves-
tigated. We have no data on help with daily activities
from non-resident carers as another possible source of
exposure of clinically vulnerable individuals attempting to
shield themselves. As we do not have individual-level data
on compliance with shielding advice, we cannot directly
evaluate the extent to which non-compliance or non-
receipt of letters might have reduced the effectiveness of
shielding advice: we can only evaluate the programme as
implemented.
As all hospital inpatients are tested for SARS-CoV-2
every few days and all deaths within 28 days of a positive
test are officially classified as deaths involving COVID-
19, some misclassification of deaths from other causes as
COVID-19 deaths is likely in those with recent hospital
exposure. However, the rate ratio associated with recent
hospital exposure was barely changed when fatal cases
without COVID-19 as underlying cause of death on death
certificate were omitted.
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Policy implications
Our results have implications for policies on shielding
the vulnerable, vaccination and control of SARS-CoV-2
transmission in the population. We have identified two
sources of exposure that are associated with severe disease
and cannot easily be avoided by those advised to shield:
in-patient hospital care and sharing a household with
other adults. Measures to allow vulnerable individuals to
reduce their exposure could include extra protection from
nosocomial infection and support for other household
members to co-isolate with the vulnerable individual.
Our findings support the policy of assigning highest
priority for vaccination to those with risk conditions eli-
gible for shielding, as these groups have markedly ele-
vated risks of severe COVID-19. For solid organ trans-
plant recipients—the group at highest risk—it is uncertain
whether the vaccine will evoke an immune response suf-
ficient to be effective [26]. As there is now evidence that
vaccination reduces transmission to household contacts
[27], one way to reduce risk in this group would be to
vaccinate their household contacts.
Policies for control of transmission in the population
and for reducing burden on health services and total
deaths have focused on population-wide reduction of
social contact. However our analysis provides compelling
evidence for a substantial contribution of nosocomial
transmission to the burden of severe COVID-19 even dur-
ing the second wave. A report for NHS England by the
Healthcare Safety Investigation Branch noted the chal-
lenges of controlling nosocomial transmission and recom-
mended that a national strategy for infection prevention
and control should be developed [28]. Vaccination of
health care workers is likely to reduce nosocomial trans-
mission, but vaccination of those booked for elective pro-
cedures should also be considered.We have not attempted
to quantify the onward transmission of COVID-19 from
discharged patients, but the PHE modelling study esti-
mated that this could have accounted for 5% of cases
requiring hospitalisation in England during the first wave
[24]. This suggests more stringent testing before dis-
charge and quarantine post discharge should be consid-
ered. More detailed understanding of how recommended
infection control policies are being operationalised is also
needed [29].
Conclusions
The effectiveness of shielding vulnerable individuals was
limited by the inability to control transmission in hos-
pital and from other adults in the household. Mitigating
the impact of the epidemic requires control of nosocomial
transmission.
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